BIOMAT Database Logo BIOMAT Database Logo

Efficacy of doxorubicin in prolymphocytic leukaemia. 1979

E König, and P Meusers, and G Brittinger

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

E König, and P Meusers, and G Brittinger
Prolymphocytic leukaemia.
February 1979, Journal of the Royal Society of Medicine,
E König, and P Meusers, and G Brittinger
Prolymphocytic leukaemia.
July 1985, Journal of the Indian Medical Association,
E König, and P Meusers, and G Brittinger
Prolymphocytic leukaemia.
May 1974, British journal of haematology,
E König, and P Meusers, and G Brittinger
Prolymphocytic leukaemia.
January 1982, Nouvelle revue francaise d'hematologie,
E König, and P Meusers, and G Brittinger
Prolymphocytic leukaemia in Uganda.
August 1975, East African medical journal,
E König, and P Meusers, and G Brittinger
Hairy-cell leukaemia and prolymphocytic leukaemia.
February 1977, Clinics in haematology,
E König, and P Meusers, and G Brittinger
Cell studies in prolymphocytic leukaemia.
December 1978, British journal of haematology,
E König, and P Meusers, and G Brittinger
Prognosis in T prolymphocytic leukaemia.
February 1986, Lancet (London, England),
E König, and P Meusers, and G Brittinger
Subretinal hypopyon in prolymphocytic leukaemia.
September 1995, The British journal of ophthalmology,
E König, and P Meusers, and G Brittinger
[Prolymphocytic leukaemia (author's transl)].
January 1979, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!